Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...
Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
Novavax Inc. closed 70.41% below its 52-week high of $23.86, which the company reached on June 6th.
Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...
Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the ...
BTIG initiated coverage of Novavax (NVAX) with a Buy rating and $19 price target The company’s standalone COVID vaccine seems to be a ...
Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.
Fourth-quarter revenue came in at $88 million, above expectations of 84 million, while Novavax continues to shift away from ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Novavax (NVAX – Research Report) and Ramsay ...
GAITHERSBURG, Md., Feb. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that the management team will participate in the following upcoming investor conferences: ...
Novavax (NVAX) delivered earnings and revenue surprises of 32% and 2.26%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 51 cents. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results